Study: COVID vaccine doesn't raise risk of myopericarditis in kids aged 5 to 11 The risk of myocarditis and/or pericarditis was not significantly different among children ages 5 to 11 years after COVID-19 vaccination from that of unvaccinated children and much lower than that among children aged 12 to 17, finds a prospective study in Denmark published today in Pediatrics.A team led by Copenhagen University Hospital researchers estimated the risk of myopericarditis (inflammation of the heart muscle and/or the membrane surrounding the heart) among 433,484 vaccinated and unvaccinated children aged 5 to 11.A total of 208,088 (48%) of the children had received at least one dose of COVID-19 vaccine from Nov 25, 2021, when the Pfizer/BioNTech vaccine was approved for this age-group in Denmark, and Feb 1, 2022.
Follow-up was 1 month.Among the vaccinated group, a previously healthy 11-year-old boy developed mild myocarditis and was hospitalized for 1 day with chest pain, shortness of breath, and elevated troponin levels 14 days after receiving his first vaccine dose.
He tested negative for COVID-19.The risk of myopericarditis was 4.8 (95% confidence interval [CI], 0.1 to 26.8) per 1 million vaccinated children aged 5 to 11 years, significantly lower than that of vaccinated children aged 12 to 17 (57.4; 95% CI, 32.1 to 94.7 per 1 million).Relative to the background incidence of myopericarditis, the risk after COVID-19 vaccination among 5- to 11-year-olds was 4.6 (95% CI, 0.1 to 156.1), not statistically different from that of those aged 12 to 17 (3.3; 95% CI, 1.4 to 8.1).
Thus, the lower risk in the younger age-group may reflect an overall lower risk of developing the condition, the authors said."In addition, SARS-CoV-2-associated